NTRK1 and cancer: Given the high clinical benefit of Trk inhibitors and the very low prevalence of NTRK fusions among major groups of human cancers, it is extremely important to define a reasonable screening strategy that, on one hand, safely detects NTRK-fusion-positive patients with high sensitivity and specificity and, on the other hand, takes into consideration additional important factors, such as cost-effectiveness, time to diagnosis, and testing feasibility due to tissue characteristics.